Notícias

Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health.

An upcoming trial result could change how investors think about the weight-loss drug market.

We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Novo Nordisk A/S (NYSE:NVO) is one of the most undervalued stocks to invest in. TheFly reported on May 27 that NVO announced that it will present new clinical findings from its cardiometabolic portfolio at the 2026 Scientific Sessions of the American […]

PFE targets a catalyst-rich 2026 with pivotal obesity and oncology studies, key data readouts, and regulatory decisions across its pipeline.

Lilly shares soared more than 18% in May.

These 5 long-term growth stocks could benefit from AI, cybersecurity, GLP-1 drugs, and fintech trends over the next decade

Eli Lilly is working on a new GLP-1 drug, and early results suggest it could be a big winner.

CVS Caremark has granted preferred formulary status to both Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo. This decision reverses Wegovy's prior commercial advantage within CVS Caremark's GLP-1 obesity drug coverage. The change affects access and competitive positioning for GLP-1 obesity therapies in CVS Caremark's network. Novo Nordisk, listed as CPSE:NOVO B, is a key player in GLP-1 based therapies, with Wegovy at the center of its obesity drug portfolio. CVS Caremark's move...

Lilly has split its stock in the past.

We just covered the Claude Stock Portfolio: Top 10 Stocks to Buy According to AI Chatbot. Eli Lilly and Company (NYSE:LLY) ranks #2 (see Claude Stock Portfolio: Top 5 Stocks to Buy According to AI Chatbot). Number of Hedge Funds: 137 Eli Lilly and Company (NYSE:LLY) is among the top stock picks of the Claude […]

Eli Lilly hits a record high after CVS expands coverage for Foundayo and Zepbound, boosting obesity drug access and raising the stakes in its rivalry with NVO.

CVS restores broader Zepbound coverage after price cuts, putting Wegovy and Zepbound on equal footing.

Eli Lilly's $1 trillion comeback is powered by the company's experimental next-generation obesity drug, Reta.

The change could improve patient access and support future sales growth.

The move gives patients broader access to Lilly's obesity drugs and strengthens competition with Novo Nordisk.

Eli Lilly shares are on pace to hit a new all-time closing high on news of increased insurance coverage for its blockbuster weight-loss drug Zepbound. Lilly shares were recently up 4.4% to $1,130.90. Pharmacy-benefit manager CVS Caremark decided to add back Lilly’s Zepbound weight-loss drug to its lists of preferred drugs.

CVS Health will reinstate coverage of Eli Lilly's weight-loss injectable Zepbound and begin coverage of the anti-obesity pill Foundayo.

CVS Health’s Caremark will resume insurance coverage of Eli Lilly’s Zepbound and separately begin covering its Foundayo weight-loss pill.

Novo Nordisk lost its lead in the GLP-1 race, but Eli Lilly's valuation is a bit rich.

Hims & Hers is acquiring Australian telehealth platform Eucalyptus as part of its international expansion plan while using $350 million in convertible senior notes.

Novo Nordisk's (NYSE:NVO) investor relations team presented at Deutsche Bank's European Champions Conference, with the broker maintaining its hold rating and DKK290 target price on the Danish pharma group. The key takeaway concerned the launch of Novo's oral semaglutide product, where the...

Small biotech firms "latch onto" AI more quickly than bigger firms, the head of ‌Chinese tech giant Tencent's healthcare division said on ‌Thursday, as more businesses embrace AI to improve efficiency. Pharmaceutical companies are also increasingly ​turning to AI to accelerate research and development, betting on new modeling tools and automated labs to improve efficiency and slash costs as well as drug development timelines. Drugmakers including Novo Nordisk ‌and Eli Lilly have ⁠announced AI-related collaborations with technology firms.

The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs will be co-preferred options

The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.

May 28 () - CVS Health said on Thursday it will add Eli Lilly's weight-loss drug Zepbound back to some ‌of its drug lists as an additional preferred option ‌for insurance coverage. Caremark, CVS' pharmacy benefit management unit, had dropped Zepbound from coverage ​on July 1 last year, while continuing to reimburse for rival Novo Nordisk's Wegovy after negotiating a more favorable price from the Danish drugmaker.

Truist called Viking a “differentiated player” in the crowded obesity market, highlighting its flagship VK2735 candidate and dual oral-plus-injectable GLP-1 strategy.

Novo Nordisk A/S (NYSE:NVO) is one of the Most Undervalued Foreign Stocks to Buy Now. On May 6, Reuters reported that Novo Nordisk A/S (NYSE:NVO) topped first-quarter profit forecasts and also raised the full-year outlook slightly. The results were driven by the company’s new Wegovy weight-loss pill, which was launched in the US in January. […]

Eli Lilly (LLY) stock has surged to new record highs of over $1,000 a share, cementing its position as one of the market's most dominant growth stories and the first pharmaceutical firm worth $1 trillion.

There is no reason to panic just yet.

Hims & Hers Health shares have slumped in 2026 as the telehealth provider moves away from selling compounded GLP-1 medications.